Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy
Jonathan D. Herman, Chuangqi Wang, John S. Burke, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 11, pp. 100811-100811
Open Access | Times Cited: 19

Showing 19 citing articles:

Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection
Ali Zhang, Hannah D. Stacey, Michael R. D’Agostino, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 6, pp. 381-396
Open Access | Times Cited: 124
Treatments for COVID-19
Hayden S. Andrews, Jonathan D. Herman, Rajesh T. Gandhi
Annual Review of Medicine (2023) Vol. 75, Iss. 1, pp. 145-157
Closed Access | Times Cited: 25
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
Paulina Kapłonek, Deniz Cizmeci, Gaurav Kwatra, et al.
Nature Immunology (2023) Vol. 24, Iss. 7, pp. 1161-1172
Open Access | Times Cited: 17
A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy of anti-receptor binding domain antibodies elicited by SARS-CoV-2 hybrid immunity
Fernanda Ana‐Sosa‐Batiz, Shailendra Kumar Verma, Norazizah Shafee, et al.
EBioMedicine (2025) Vol. 113, pp. 105619-105619
Open Access
Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies
Maike Janssen, Albrecht Leo, Cornelia Wolf, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 4, pp. 618-626
Open Access | Times Cited: 3
Association between COVID-19 convalescent plasma antibody levels and COVID-19 outcomes stratified by clinical status at presentation
Hyung Park, Chang Yu, Liise‐anne Pirofski, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19
Sam Afkhami, Alisha Kang, Vidthiya Jeyanathan, et al.
Current Opinion in Virology (2023) Vol. 61, pp. 101334-101334
Open Access | Times Cited: 9
Generating the Evidence Base for Convalescent Plasma Use for a New Infectious Disease
Hyunah Yoon, Liise‐anne Pirofski
Current topics in microbiology and immunology (2024)
Closed Access | Times Cited: 2
Antibody Fc receptor binding and T cell responses to homologous and heterologous immunization with inactivated or mRNA vaccines against SARS-CoV-2
Carolyn A. Cohen, Nancy Leung, Prathanporn Kaewpreedee, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
COVID-19 convalescent plasma boosts early antibody titer and does not influence the adaptive immune response
John F. McDyer, Mahzad Azimpouran, Valerie Durkalski‐Mauldin, et al.
JCI Insight (2023) Vol. 8, Iss. 8
Open Access | Times Cited: 5
1,7-Bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one inhibits SARS-CoV-2 by targeting the nucleocapsid protein
Yang Liu, Kuiru Sa, Wei Xu, et al.
Acta Materia Medica (2023) Vol. 2, Iss. 3
Open Access | Times Cited: 5
A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection
Stephen Boulton, Joanna Poutou, Rida Gill, et al.
Molecular Therapy — Methods & Clinical Development (2023) Vol. 31, pp. 101110-101110
Open Access | Times Cited: 5
Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 outpatients: a multi-center, non-inferiority, open-label randomized controlled trial (PlasMab)
Taweegrit Siripongboonsitti, Nuttakant Nontawong, Kriangkrai Tawinprai, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 6
Open Access | Times Cited: 5
Fc-mediated functions and the treatment of severe respiratory viral infections with passive immunotherapy – a balancing act
Hillary A. Vanderven, Stephen J. Kent
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Passive antibody therapy in emerging infectious diseases
Xiaoming Yang
Frontiers of Medicine (2023) Vol. 17, Iss. 6, pp. 1117-1134
Closed Access | Times Cited: 3
Binding of SARS-CoV-2 nucleocapsid protein to uninfected epithelial cells induces antibody-mediated complement deposition
Jamal Fahoum, Maria Billan, Julia K. Varga, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Retrospective Analysis of Coronavirus SARS‐CoV‐2 Antibody Levels in COVID‐19 Convalescent Plasma From Blood Donors
Ji He, Yanjun Zhang, Jie Dong, et al.
Canadian Journal of Infectious Diseases and Medical Microbiology (2024) Vol. 2024, Iss. 1
Open Access
COVID-19 Convalescent Plasma Therapy: Long-term Implications
Hyunah Yoon, Yi Li, Keith Goldfeld, et al.
Open Forum Infectious Diseases (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 1
On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
Daniele Focosi, Massimo Franchini, Arturo Casadevall
Viruses (2022) Vol. 14, Iss. 11, pp. 2378-2378
Open Access | Times Cited: 2
Page 1

Scroll to top